Literature DB >> 23631743

Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials.

Aung Naing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23631743     DOI： 10.1517/13543784.2013.795947

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


× No keyword cloud information.
  4 in total

1.  Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Authors:  Monica Mita; Siqing Fu; Sarina Anne Piha-Paul; Filip Janku; Alain Mita; Ronald Natale; Wei Guo; Charles Zhao; Razelle Kurzrock; Aung Naing
Journal:  Invest New Drugs       Date:  2017-02-13       Impact factor: 3.850

2.  Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.

Authors:  Xiaochun Liu; Patricia Lorusso; Monica Mita; Sarina Piha-Paul; David S Hong; Siqing Fu; Lacey McQuinn; Ekaterine Asatiani; Lawrence A Doyle; Helen X Chen; Kenneth R Hess; Razelle Kurzrock; Aung Naing
Journal:  Oncologist       Date:  2014-03-25

Review 3.  Hepatocellular carcinoma: Where there is unmet need.

Authors:  Manojkumar Bupathi; Ahmed Kaseb; Funda Meric-Bernstam; Aung Naing
Journal:  Mol Oncol       Date:  2015-06-25       Impact factor: 6.603

Review 4.  Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities.

Authors:  Tan Li; Guanyu Wang
Journal:  Int J Mol Sci       Date:  2014-10-20       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.